Early Switch to Dexamethasone Implantation In Patients With Diabetic Macular Edema Resistant To Aflibercept: Short-Term Results Aflibercept'e Dirençli Diyabetik Maküla Ödemi Olan Hastalarda Deksametazon Implantına Erken Geçiş: Kısa Dönem Sonuçlar


Bayat A. H., Erden B., ÇAKIR A., Bölükbaşi S., Baş E., ELÇİOĞLU M. N.

Retina-Vitreus, cilt.28, sa.4, ss.389-394, 2019 (Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 4
  • Basım Tarihi: 2019
  • Dergi Adı: Retina-Vitreus
  • Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.389-394
  • Anahtar Kelimeler: Dexamethasone, Diabetic macular edema, Optical coherence tomography
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Purpose: To evaluate the efficacy of early switch to intravitreal dexamethasone implantation (IDI) in aflibercept resistant diabetic macular edema (DME) Materials and methods: In this retrospective study 21 eyes of 21 patients with persistent diabetic macular edema, who underwent a single dose IDI were examined. All of the patients had a history of at least five intravitreal aflibercept (IVA) injections. Main outcome measures were changes in best-corrected visual acuity (BCVA), central macular thickness (CMT) at 1, 2, 3 months after IDI treatment. Results: Mean follow-up time and average number of previous IVA injections was 19.24±1.67 months and 5.35±0.6. The mean BCVA was improved from 0.73±0.57logMAR to 0.49±0.34logMAR (p=0.011), 0.34±0.29 logMAR(p=0.001), and 0.36±0.27 logMAR(p=0.001) at 1, 2 and 3 months, respectively. The mean CMT was decreased from 434±90 μm to 335±74 μm (p<0.001), 328±46 μm (p<0.001) and 350±85 μm (p=0.009) at 1, 2 and 3 months. Conclusion: Intravitreal dexamethasone implantation resulted in a significant improvement in visual and anatomical outcomes in patients with aflibercept resistant diabetic macular edema.